Vanadium in cancer treatment

Critical Reviews in Oncology/Hematology

Volumn 42, Issue 3, 2002, Pages 249-265

  Evangelou, Angelos M ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Anticancer effects; Apoptosis; Biochemistry; Drug resistance; Free radicals; Metastasis; Toxicity; Vanadium

Indexed keywords

CELL ENZYME; DNA; DNA FRAGMENT; ENZYME; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TYROSINE PHOSPHATASE; TYROSINE PHOSPHORYLASE; UNCLASSIFIED DRUG; VANADIUM; XENOBIOTIC AGENT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BIOCHEMISTRY; CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL CYCLE; CELL LINE; CELL MEMBRANE; CELL PROLIFERATION; CELLULAR PARAMETERS; CHEMICAL REACTION; CLINICAL TRIAL; CYTOTOXICITY; DNA CLEAVAGE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERANCE; ENZYME INHIBITION; GENE ACTIVATION; HUMAN; LIPID PEROXIDATION; METASTASIS; METASTASIS INHIBITION; NONHUMAN; OXIDATIVE STRESS; REDUCTION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; CELL DIVISION; DRUG RESISTANCE; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; ORGANOMETALLIC COMPOUNDS; OXIDATIVE STRESS; PHARMACOKINETICS; VANADIUM;

EID: 0036273321     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(01)00221-9     Document Type: Review

References (186)

1. History occurrence and uses of vanadium
2. Vanadium
3. Vanadium accumulation and subcellular distribution in relation to vanadate-induced cytotoxicity in vitro
4. The effects of chelating agents on vanadium distribution in the rat body and uptake by human erythrocytes
5. A possible role of oxidative stress in the vanadium-induced cytotoxicity and the MC3T3E1 osteoblast and UMR106 osteosarcoma cell lines
6. Studies on the antineoplastic effect of vanadium salts
7. Antitumor activity of vanadium compounds
8. Vanadium stimulates (Na, K)ATPase in friend erythroleukemia cells and blocks erythropoiesis
9. Dietary vanadyl (IV) sulfate inhibits chemically-induced mammary carcinogenesis
10. Vanadium compounds. Biological actions and potential as pharmacological agents
11. Insulin-like effects of vanadium. Basic and clinical implications
12. The role of vanadium in the management of diabetes
13. Peroxo heteroligant vanadates (V): Synthesis, spectra-structure relationships and stability toward decomposition
14. Antitumor activity of peroxo heteroligant vanadates (V) in relation to biochemistry of vanadium
15. From Vanadis to Atropos: Vanadium compounds as pharmacological tools in cell death signaling
16. 2 and vanadate concomitantly stimulates protein tyrosine phosphorylation and polyphosphoinositide breakdown in different cell lines
17. 2 and vanadate in vitro
18. Peroxovanadium compounds. A new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics
19. Complexes of metals other than platinum as antitumor agents
20. Molecular genotoxicity profiles of apoptosis-inducing vanadocene complexes
21. Antitumor metallocenes: Structure-activity studies and interactions with biomolecules
22. Vanadocene mediated in vivo male germ cell apoptosis
23. Apoptosois-inducing vanadocene compounds against human testicular cancer
24. In vitro cell growth inhibition by metallocene dichlorides
25. Tumor inhibition by metalocenes: Ultrastructural localization of titanium and vanadium in treated tumor cells by electron energy loss spectroscopy
26. Non-platinum-group metal antitumor agents. History, current status, and perspectives
27. Antitumor and toxicologic properties of the organometallic anticancer agent vanadocene dichloride
28. Bis-cyclopentadienyl compounds of Ti, Zr V, Nb and Ta
29. Use of vanadate as protein-phsphotyrosine phosphate inhibitor
30. 2
31. One electron reduction of vanadate by ascorbate and related free radical generation at physiological pH
32. Solution properties of vanadium (III) with regard to biological systems
33. Synthetic analogues for oxovanadium (IV/V)-glutathione interaction: An EPR, synthetic and structural study of oxovanadium(IV) compounds with sulfhydryl-containing pseudopeptides and dipeptides
34. Synthetic analogues for oxovanadium (IV/V)-glutathione interaction: An NMR, EPR, synthetic and structural study of oxovanadium (IV/V) compounds with sulfhydryl-containing pseudopeptides and dipeptides
35. The intensity of vanadium (V)-induced cytotoxicity and morphological transformation in BALB/3T3 cells is dependent on glutathione mediated bioreduction to vanadium
36. Hydroxyl radical generation ind the NADH/microsomal reduction of vanadate
37. Flavoenzymes reduce vanadium (V) and molecular oxygen and generate hydroxyl radical
38. Acute toxicity of amonium metavanadate in mice
39. Comparison of the therapeutic effects of two vanadium complexes administered at low doses on benzo(α)-pyrene induced malignant tumors in rats
40. Beneficial effects of a vanadium complex with cysteine administered at low doses on benzo(α)pyrene-induced leiomyosarcomas in Wistar rats
41. Antitumor effects of a vanadium complex with cysteine on malignant cell lines and tumor-bearing Wistar rats
42. Does vanadium play a role in cellular regulation?
43. Vanadate as phosphate analogs in biochemistry
44. Peroxovanadium compounds: Biological actions and mechanism of insulin-mimetics
45. In vivo insulin mimetic effects of pV compounds: Role for tissue targetting in determining potency
46. Mechanisn of inhibition of protein-tyrosine phosphatases by vanadate and pervanadate
47. Crystal structure of bovine low molecular weght phosphotyrosyl phophatase complexed with the transition state analog vanadate
48. Role of oxidative stress in the action of vanadium phosphotyrosine phosphatase inhi-bitors
49. Vanadium activates or inhibits receptor and non-receptor tyrosine kinases in cell-free experiments, depending on its oxidation state. Possible role of endogenous vanadium in controlling cellular protein kinase activity
50. Relations between iron and vanadium metabolism. The exchange of vanadium between transferin and ferritin
51. Electron paramagnetic studies and insulin like effects of vanadium in rat adipocytes
52. Vanadate inhibits the red cell (Na,K)ATPase from the cytoplasmic side
53. The transport and accumulation of oxyvanadium compounds in human erythocytes in vitro
54. Detection of oxovanadium (IV) and characterization of its ligand environment in subcellular fractions of the liver of rats treated with pentavalent vanadium (V)
55. Isolation properties and structural studies on a compound from tunicate blood cells that may be involved in vanadium accumulation
56. Metabolic patterns of vanadium in the rat
57. Vanadium retention in rat tissues following acute exposures to different dose levels
58. Retention of intratrachealy instilled and ingested tetravalent and pentavalent vanadium in rat
59. Vanadyl (IV) and vanadate (V) binding to selected endogenous phosphate, carboxyl and amino ligands; Calculations on cellular vanadium species distribution
60. The relationship between insulin and vanadium metabolism in insulin target tissues
61. Toxicology of vanadium compounds in diabetic rats: The action of chelating agents on vanadium accumulation
62. Distribution of titanium and vanadium followed repeated injection of high-dose salts
63. Kinetic analysis of uptake distribution and excretion of 48V-labeled compounds in rats
64. Vanadium distribution in rats and DNA cleavage by vanadyl complex: Implication for vanadium toxicity and biological effects
65. Comparison between concentrations of trace elements in normal and neoplastic human breast tissue
66. Localizing efficiency of (48)vanadyl-pheophorbide in tumors as anew tumor imaging agent
67. Oral vanadyl sulfate improves hepatic and periferal insulin sensitivity in patients with non-insulin-dependent diabetes mellitus
68. Metabolic effects of sodium metavanadate in humans with insulin-dependent and non-insulin-dependent diabetes mellitus
69. Effects of vandyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus
70. Effects of vanadium on serum cholesterol
71. Oral vanadyl sulfate does not affect blood cells, viscocity or biochemistry in humans
72. Short-term toxicity studies of vanadium in rats
73. Vanadium salts induce cytogenic efects in in vivo treated mice
74. Effects of vanadium on activity and learning in rats
75. Vanadium: A review of the reproductive and developmental toxicity
76. Effects of maternal vanadate treatment on fetal development
77. Toxicity studies on one-year treatment of non-diabetic and streptozotocin-induced diabetic rats with vanadyl sulfate
78. Lack of hematological effect of oral vanadium treatment in rats
79. Time and dose-response study on the effects of vanadate on rats: Morphological and biochemical changes in organs
80. Vanadium and diabetes. What about vanadium toxicity?
81. Reprotoxic and genotoxic studies of vanadium pentoxide (V2)O(5) in male mice. II. Effects in several mouse tissues
82. Influence of chelating agents on the toxicity, distribution and excretuion of vanadium in mice
83. Effect of vanadate of PHA-induced proliferation on human lymphocytes from young and old subjects
84. Oxidative stress-regulated gene expression and promotion of morphological transformation induced in C3H/10T1/2 cells by ammonium metavanadate
85. Vanadate-induced gene expression in mouse C127 cells: Role of oxygen derived active species
86. Vanadium as a modulator of cellular regulatory cascades and oncogene expression
87. The importance of free radicals and catalytic metal ions in human disease
88. Free radicals 'reactive species' and toxicology
89. Vanadium chemoprevention of 7,12-dimethybenz(α)anthracene-induced rat mammary carcinogenesis: Probable involvement of representative hepatic phase I and II xenobiotic metabolizing enzymes
90. Inhibitory effect of vanadium on rat liver carcinogenesis initiated with diethylnitrosamine and promoted by phenobarbital
91. Vanadium mediated chemoprevention against chemical hepatocarcinogenesis in rats: Haematological and histological characterisitics
92. Differential modulation of xenobiotic metabolizing enzymes by vanadium during diethylnitrosamine-induced hepatocarcinogenesis in Sprangue-Dawley rats
93. Inhibition of diethylnitrosamine-induced rat liver chromosomal aberrations and DNA-strand breaks by synergisitc supplementation of vanadium and 1alpha-25-dihydroxyvitamin D(3)
94. Protective role of vanadium in the survival of hosts during the growth of atransplantable murine lymphoma and its profound effects on the rates and patterns of biotransformation
95. Enhanced erythropoietin and suppression of γ-glutamyl transpeptidase(GTT) activity in murine lymphoma following administration of vanadium
96. Vanadium: A modifier of drug metabolizing enzyme patterns and its critical role in cellular proliferation in transplantable murine lymphoma
97. In vitro and in vivo antineoplastic effects of orthovanadate
98. Vanadate supplements and 1,2-methylhydrazine-induced colon cancer in mice: Increased thymidine incorporation without enhanced carcinogenesis
99. Inhibitors of tyrosine phosphorylation induce apoptosis in human leukemic cell lines
100. A comparqative study of plasma Mg2+-ATPase activities in normal, regenerating and malignant cells
101. Vanadate inhibits expression of the gene phosphoenolpyruvate carboxykinase (GTP) in rat hepatoma cells
102. Expression of c-myc gene in human ovary carcinoma cells treated with vanadate
103. Mechanism for a new vanadium complex: Hydroxyl radical-dependent DNA cleavage by 1,10-phenanthroline-vanadyl complex in the presence of hydrogen peroxide
104. Vanadate, alcohol or both increase passive membrane permeability of neuro-2a cells; Lesser sensitivity of Hep-2 cells
105. Vanadium compounds. Their action on alkaline phosphatase activity
106. Antitumor activities of vanadium (IV), manganese (IV), iron (III), cobalt (II) aqnd copper (II) complexes of 2-methylaminopyridine
107. 2) co-ordination mode, and evaluation of its effects on uptake of D-glucose by Ehrlich ascites tumor cells
108. Arrest of the G2/M transition of the cell cycle by protein tyrosine phosphatase inhibition: Studies on a neuronal and a glial cell line
109. +-ATPase activity in cultured C6 glioma cells
110. Vanadium induces AP-1 and NF-kappaB dependent transcription activity
111. Vanadate induces P53 activation through hydrogen peroxide and causes apoptosis
112. Vanadate induces apoptosis in epidermal JB6+ cells via hydrogen-peroxide mediated reactions
113. Vanadate-induced activation of activator protein-1. Role of reactive oxygen species
114. Suppression of metastatic potential of high-metastatic Lewis lung sarcoma cells by vanadate, an inhibitor of tyrosine phosphotase, through inhibiting cell-substrate adhesion
115. Pervanadate elicits proliferation and mediates mitogen-activated protein (MAP)
116. Biphasic effects of vanadium salts on in vitro tumor colony growth
117. Vanadium-induced kB dependent transcription depends upon peroxide-induced activation of p38 mitogen-activated protein kinase
118. Metallocene ineractions with DNA and DNA-processing enzymes
119. Aqueous coordination chemistry of vanadocene dichloride, with nucleotides and phosphoesters. Mechanistic implication for a new class of antitumor agents
120. 2 with calf thymus DNA
121. 2 with nucleic acid constituents
122. Sequestration of mitotic (M-phase) chromosomes in autophagosomes. Mitotic programmed cell death in human Chang liver cells induced by an OH* burst from vanadyl (IV)
123. Genotoxicity of vanadium pentoxide evaluated by the single cell gel electrophore- Sis in human lymphocytes
124. Generation of putative intrastrand cross-links and strand breaks in DNA by transition metal ion-mediated oxygen radical attack
125. Comparison of the formation of 8-hydroxy-2'-deoxyguanosine and single- and double-strand breaks in DNA meiated by fenton reactions
126. Apoptosis: Inhibitor or instigator of carcinogenesis?
127. Apoptosis in the pathogenesis and treatment of diseases
128. Vanadate induction of NF-κB involves IκB kinase β and SARK/ERK kinase in macrophages
129. Vanadium salts stimulate mitogen-activated protein (MAP) kinases and ribosomal S6 kinases
130. Multiple signals converging on NF-kappaB
131. Nuclear factor-kB, cancer and apoptosis
132. Lineage-specific induction of B cell apoptosis and altered signal transduction by the phosphotyrosine inhibitor bis(maltolato) oxovanadium (IV)
133. Tyrosine phosphorylation and morphological transformation induced by four vanadium compounds on MC3T3E1 cells
134. Phosphotysyl protein phospatases: Potential regulators of cell proliferation and differentiation
135. Impact of oxidative stress on signal trunsduction control by phosphotyrosine phosphatases
136. The enhancement by pervanadate of tyrosine phosphorylation on prostatic proteins occurs through the inhibition of membrane-associated tyrosine phosphatases
137. Orthovanadate, an inhibitor of protein tyrosine phospahatases acts more potently as a promoter than an inhibitor in the BALB/3T3 cell transformation
138. Phosphatidylinositol 3-kinase requirement in activation of the ras/C-raf-1/MEK/ERK and p70s6k signaling cascade by the insulinomimetic agent vanadyl sulfate
139. Activation of MAPKs in human bronchial epithelial cells exposed to metals
140. Arsenite exposure of cultured airway epithelial cells activates kB-dependent Interleukin-8 Gene expression in the absence of nuclear factor kB nuclear translocation
141. The cellular response to oxidative stress: Influences of mitogen-activated protein kinase signaling pathways on cell survival
142. MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1
143. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis
144. Activation of mitogen-activated protein (MAP) kinases pathway be pervanadate, a potent inhibitor of tyrosine phosphatases
145. lck, ZAP-70, SLP-76, and calcium-regulated effectors are involved in NF-κB activation by bisperoxovanadium phosphotyrosyl phosphate inhibitors in human T-cells
146. Mitochondria and apoptosis
147. Poly(ADP-ribosyl)ation, genomic instability and longevity
148. Prognostic significance of p53 in the cancer of the larynx
149. Bis(4,7-dimethyl 1-1, 10 phenanthroline)sulfatooxovanadium (IV) as a novel apoptosis-inducing anticancer agent
150. Oxidative mechanisms and toxicity of metal ions
151. Free radicals, antioxidant enzymes and carcinognenesis
152. Tetravalent vanadium releases ferritin ion which stimulates vanadium-dependent lipid peroxidation
153. Vanadium redox cycling, lipid peroxidation and coxygenation of benzo(α)pyrene,7,8-dihydrodiol
154. Mechanism of vanadate-induced activation of tyrosine phophorylation and of the respiratory bgurst in HL60 cells. Role of reduced oxygen metabolites
155. Vanadium lipid peroxidation: Evidence for involvement of vanadyl and hydroxyl radicals
156. Impaired antioxidant status in diabetic rat live. Effect of vanadate
157. Selective enhancement of glutathione S-tranferase activity in liver and extrahepatic tissues of rat following oral administration of vanadate
158. Time course effects of vanadium supplement on cytosolic reduced glutathione level and glutathione S-transferase activity
159. Vanadium effects on the activity of horseradish peroxidase, catalase, glutathione peroxidase, and superoxide dismutase in vitro
160. The inhibitory effect of vanadium oxyanions on the activity of copper-zinc superoxide dismutase
161. Cadherin-mediated cell-cell adhesion is perturbed by the v-src tyrosine phosphory-lation in metastatic fibroblasts
162. Induction of endothelial cell surface adhesion molecules by tumor necrosis factor is blocked by protein tyrosine phosphatase inhibitors: Role of nuclear transcription factor NF-κB
163. Tumor derived mutated E-cadherin influences beta-catenin localization and increases susceptibility to actin cytoskeletal changes induced by pervanadate
164. The role of adhesive proteins in the hematogenous spread of cancer
165. Adhesion molecules in clinical medicine
166. Soluble fibrin augments platelet tumor cell adherance in vitro and in vivo and enhances experimental metastasis
167. Tumor-induced platelet aggregation and growth promoting factors as determinants for succesful tumor metastasis
168. Secretion of urokinase and metalloproteinase-9 induced by asturosporine is dependent on tyrosine kinase pathway in mammary tumor cells
169. Integrin-dependent protein dephosphorylation on tyrosine induced by activation of the thrombin receptor in human platelets
170. Platelet-aggregating activities of metastasizing tumor cells. Effects of cell surface modification on thrombin generation, platelet aggregation and subsequent colonization
171. Okadaic acid and vanadate inhibit collagen-induced platelet aggregation: The functional relation of phosphatases on platelet aggregation
172. Tyrosine residue in exon 14 of the cytoplasmic domain of platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31), regulates ligand binding specificity
173. ATPAse activity of partially purified P-glycoprotein from multidrug resistant Chinese hamster ovary cells
174. Drug binding sites on P-glycoprotein are altered by ATP binidng prior to nucleotide hydrolysis
175. Vanadate-resistant mutants of Saccharomyces cerevisiae show alterations in protein phophorylation and growth control
176. Defective plasma membarane H(+)-ATPase or orthovanadate resistant mutants from Candida albicans, a pathogenic yeast
177. Effects of modulators on the ATPase activity and vanadate nucleotide trapping of human P-glycoprotein
178. Characterization of the adenosine triphosphate activity of Chinese hamster P-glycoprotein
179. Vanadate is toxic to adherent-growing multidrug-resistant cells
180. Study of sodium orthovanadate as a reverser of multidrug resistance on lymphoblastic leukemic CEM/VLB100 cells
181. GTP-stimulated phosphorylation of P-glycoprotein in transporting vesicles from KB-V1 multidrug resistant cells
182. The cytotoxic interaction of inorganic trace elements with EDTA and cisplatin in sensitive and resistant human avarian cancer cells
183. Decreased tyrosine phosphorylation in tumor cells resistant to FCE 24517
184. Modulation of cytotoxic activity of tumor necrosis factor by protein tyrosine phosphatase inhibitors